Drug intelligence / Profile preview

heat-killed Escherichia coli ST38

Development stage
Preclinical
Lead developer
The University of Queensland
Modality
Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration
Subcutaneous, Intramuscular, Intraperitoneal
01

Overview

Heat-killed Escherichia coli ST38 is an experimental whole-cell inactivated vaccine (WCV) candidate and research tool used in the study and prevention of sepsis and extraintestinal pathogenic *Escherichia coli* (ExPEC) infections. Developed by researchers at the University of Queensland, it consists of *E. coli* bacteria from the ST38 sequence type—a lineage frequently associated with carbapenem resistance and OXA-48 carbapenemase production—that have been rendered non-viable through heat treatment. This inactivation process preserves the structural integrity of various pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharide (LPS), peptidoglycan, and outer membrane proteins. When used as a vaccine, it stimulates the innate immune system via Toll-like receptors (primarily TLR4 and TLR2) and induces an adaptive immune response, including the production of opsonizing antibodies and T-cell activation. In preclinical research, it is employed in murine models of abdominal gram-negative sepsis to evaluate host immune dynamics and the efficacy of immunization strategies against multidrug-resistant bacterial strains.

Other names
Heat-killed E. coli ST38Inactivated E. coli ST38 vaccineHK-ST38HK-ST-38HK-ST 38
02

Targets

TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on heat-killed Escherichia coli ST38.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on heat-killed Escherichia coli ST38.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call